Drugs & Targets Pronai Therapeutics obtains exclusive license to develop and commercialize PNT737 September 30, 2016Vol.42 No.36
Drugs & Targets Multiple Myeloma Research Foundation Contributes Data to NCI Genomic Data Commons September 30, 2016Vol.42 No.36
Drugs & Targets Prix Galien Foundation announces “Discovery of the Decade” nominees September 30, 2016Vol.42 No.36
Drugs & Targets Genomics England Partners with GenomOncology on 100,000 Genomes Project September 30, 2016Vol.42 No.36
Drugs & Targets Boehringer Ingelheim and ViraTherapeutics to collaborate on oncolytic virus therapy platform September 30, 2016Vol.42 No.36
Drugs & Targets Janssen submits supplemental FDA New Drug Application for ibrutinib September 30, 2016Vol.42 No.36
UMich Appoints Research Leadership Team; Goldberg to Retire at Ohio State-James September 30, 2016Vol.42 No.36
Conversation with The Cancer Letter NCI’s Care Delivery Research Program Seeks to Involve Scientists from Other Fields September 30, 2016Vol.42 No.36By Paul Goldberg
Conversation with The Cancer Letter OHSU Seeks to Raise another $1 Billion; Keith Todd Describes the Strategy September 23, 2016Vol.42 No.35By Paul Goldberg
In Brief Falk Medical Research Trust awards $485,000 for uveal melanoma research September 23, 2016Vol.42 No.35
